Synonyms: ASG-22CE | enfortumab vedotin-ejfv | Padcev®
enfortumab vedotin is an approved drug (FDA (2019), EMA (2022))
Compound class:
Antibody
Comment: Enfortumab vedotin is an anti-Nectin 4 monoclonal antibody-drug conjugate [3]. The toxic payload is monomethyl auristatin E (MMAE; PubChem CID 11542188). It exhibits potent efficacy in multiple preclinical cancer models [1].
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2019) | EMA (2022) | China NMPA (2024) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9821 | enfortumab vedotin |
Synonyms ![]() |
ASG-22CE | enfortumab vedotin-ejfv | Padcev® |
Database Links ![]() |
|
GtoPdb PubChem SID | 405067331 |
Search PubMed clinical trials | enfortumab vedotin |
Search PubMed titles | enfortumab vedotin |
Search PubMed titles/abstracts | enfortumab vedotin |